Cure Ventures

VC firm · Boston, MA

Verified active in the last 12 monthsSEC-registered adviser

Venture firm based in Boston, MA. Most recent fund on file: Cure Ventures Fund I, L.P. ($350M offering), filed Apr 2023. Partners sit on the boards of 3 startups that raised recently.

“Standard of Cure Embracing Evidence. Increasing Success. Saving Lives. How We Go All-In With Entrepreneurs, We Bring Cures to Life Learn More Our People Moving Medicine Forward Dr. Michael Aberman XenImmune Leveraging the robust immune response to target tumors like never before. Read Michael’s Story Dr. Milenko Cicmil Tasca Therapeutics Unlocking post-translational modification to expand […]” (from the firm’s website)

Stages: Seed to Growth
Typical check (est.): $3.5M–$10.5M
Latest fund: Undisclosed · Dec 2025
Last verified activity: Dec 2025

Focus

Biotech & Pharma

Recent portfolio activity

Alessa Therapeutics
Board seat · CA
May 2025
Tasca Therapeutics
Board seat · MA
Nov 2024
RYNE Biotechnology
Board seat · MA
Mar 2024

Funds and vehicles on SEC file

Cure Ventures Fund II, L.P.
Fund
Dec 2025
Cure Ventures Fund I, L.P.
Fund · $350M offering
Apr 2023

Sources

SEC Form D: Cure Ventures Fund II, L.P.Dec 18, 2025
SEC Form D: Cure Ventures Fund I, L.P.Apr 4, 2023
SEC adviser record: Cure Ventures Management, LPMar 11, 2026
Firm websiteOct 12, 2026

Profile last verified Oct 12, 2026. Is this you? Correct or remove this profile.